PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BMY vs. MRK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


BMYMRK
YTD Return-12.84%18.39%
1Y Return-31.61%11.46%
3Y Return (Ann)-8.59%24.77%
5Y Return (Ann)1.22%14.40%
10Y Return (Ann)1.66%12.05%
Sharpe Ratio-1.550.68
Daily Std Dev21.30%17.34%
Max Drawdown-70.62%-68.63%
Current Drawdown-42.91%-2.80%

Fundamentals


BMYMRK
Market Cap$90.90B$332.33B
EPS-$3.10$0.91
PE Ratio12.68144.18
PEG Ratio2.240.10
Revenue (TTM)$45.53B$61.40B
Gross Profit (TTM)$36.38B$42.08B
EBITDA (TTM)$18.20B$10.21B

Correlation

-0.50.00.51.00.5

The correlation between BMY and MRK is 0.51, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Performance

BMY vs. MRK - Performance Comparison

In the year-to-date period, BMY achieves a -12.84% return, which is significantly lower than MRK's 18.39% return. Over the past 10 years, BMY has underperformed MRK with an annualized return of 1.66%, while MRK has yielded a comparatively higher 12.05% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


15,000.00%20,000.00%25,000.00%30,000.00%December2024FebruaryMarchAprilMay
13,965.01%
31,061.32%
BMY
MRK

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Bristol-Myers Squibb Company

Merck & Co., Inc.

Risk-Adjusted Performance

BMY vs. MRK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BMY
Sharpe ratio
The chart of Sharpe ratio for BMY, currently valued at -1.55, compared to the broader market-2.00-1.000.001.002.003.004.00-1.55
Sortino ratio
The chart of Sortino ratio for BMY, currently valued at -2.15, compared to the broader market-4.00-2.000.002.004.006.00-2.15
Omega ratio
The chart of Omega ratio for BMY, currently valued at 0.72, compared to the broader market0.501.001.500.72
Calmar ratio
The chart of Calmar ratio for BMY, currently valued at -0.77, compared to the broader market0.002.004.006.00-0.77
Martin ratio
The chart of Martin ratio for BMY, currently valued at -1.71, compared to the broader market-10.000.0010.0020.0030.00-1.71
MRK
Sharpe ratio
The chart of Sharpe ratio for MRK, currently valued at 0.68, compared to the broader market-2.00-1.000.001.002.003.004.000.68
Sortino ratio
The chart of Sortino ratio for MRK, currently valued at 1.16, compared to the broader market-4.00-2.000.002.004.006.001.16
Omega ratio
The chart of Omega ratio for MRK, currently valued at 1.13, compared to the broader market0.501.001.501.13
Calmar ratio
The chart of Calmar ratio for MRK, currently valued at 0.83, compared to the broader market0.002.004.006.000.83
Martin ratio
The chart of Martin ratio for MRK, currently valued at 1.58, compared to the broader market-10.000.0010.0020.0030.001.58

BMY vs. MRK - Sharpe Ratio Comparison

The current BMY Sharpe Ratio is -1.55, which is lower than the MRK Sharpe Ratio of 0.68. The chart below compares the 12-month rolling Sharpe Ratio of BMY and MRK.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.00December2024FebruaryMarchAprilMay
-1.55
0.68
BMY
MRK

Dividends

BMY vs. MRK - Dividend Comparison

BMY's dividend yield for the trailing twelve months is around 5.35%, more than MRK's 2.34% yield.


TTM20232022202120202019201820172016201520142013
BMY
Bristol-Myers Squibb Company
5.35%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%2.46%3.31%
MRK
Merck & Co., Inc.
2.34%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.42%3.11%3.45%

Drawdowns

BMY vs. MRK - Drawdown Comparison

The maximum BMY drawdown since its inception was -70.62%, roughly equal to the maximum MRK drawdown of -68.63%. Use the drawdown chart below to compare losses from any high point for BMY and MRK. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%December2024FebruaryMarchAprilMay
-42.91%
-2.80%
BMY
MRK

Volatility

BMY vs. MRK - Volatility Comparison

Bristol-Myers Squibb Company (BMY) has a higher volatility of 9.79% compared to Merck & Co., Inc. (MRK) at 4.17%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%December2024FebruaryMarchAprilMay
9.79%
4.17%
BMY
MRK

Financials

BMY vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items